Paul Peng

Paul Peng is the Head of Oncology, Hematology, and Rare Disease Business Unit at Amgen, where they lead initiatives to expand patient access and improve treatment pathways. With over twenty years of experience in the pharmaceutical industry, Paul has a proven track record of driving strategic growth and forming high-performing teams across multiple regions, including LATAM, MEA, Asia, Australia, and Russia. Paul previously held positions at AstraZeneca, Roche, and Novartis, focusing on commercial operations and business development. Currently enrolled in the Executive MBA program at Kellogg-HKUST, Paul continues to deepen their expertise in business administration and management.